BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31405269)

  • 21. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
    Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
    Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma.
    Tsai WL; Sun WC; Chen WC; Chiang CL; Lin HS; Liang HL; Cheng JS
    Medicine (Baltimore); 2020 Aug; 99(32):e21489. PubMed ID: 32769883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
    Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
    Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    Masuda K; Ono A; Aikata H; Kawaoka T; Nelson Hayes C; Teraoka Y; Daijo K; Nakamura-Inagaki Y; Morio K; Fujino H; Kan H; Uchida T; Masaki K; Kobayashi T; Nakahara T; Makokha GN; Zhang Y; Nagaoki Y; Miki D; Tsuge M; Hiramatsu A; Imamura M; Abe-Chayama H; Kawakami Y; Ochi H; Chayama K
    J Gastroenterol; 2018 Jan; 53(1):107-118. PubMed ID: 28474222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
    Lee BH; Lee DS; Cho CW; Yun SS
    World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization].
    Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Okano N; Kikuchi Y; Igarashi Y; Sumino Y
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):953-6. PubMed ID: 26321708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization.
    Sumie S; Yamashita F; Ando E; Tanaka M; Yano Y; Fukumori K; Sata M
    AJR Am J Roentgenol; 2003 Nov; 181(5):1327-34. PubMed ID: 14573429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma.
    Hsieh CB; Chang HM; Chen TW; Chen CJ; Chan DC; Yu JC; Liu YC; Chang TM; Shen KL
    World J Gastroenterol; 2004 Feb; 10(4):505-8. PubMed ID: 14966906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas.
    Saccheri S; Lovaria A; Sangiovanni A; Nicolini A; De Fazio C; Ronchi G; Fasani P; Del Ninno E; Colombo M
    J Vasc Interv Radiol; 2002 Oct; 13(10):995-9. PubMed ID: 12397120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study.
    Kim JK; Kim JW; Lee IJ; Joo SM; Lee KH; Cho ES; Yu JS; Jeon TJ; Kim Y; Lee JI; Lee KS
    Radiat Oncol; 2017 Aug; 12(1):133. PubMed ID: 28810886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
    Ye HH; Ye JZ; Xie ZB; Peng YC; Chen J; Ma L; Bai T; Chen JZ; Lu Z; Qin HG; Xiang BD; Li LQ
    World J Gastroenterol; 2016 Apr; 22(13):3632-43. PubMed ID: 27053855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
    Fukubayashi K; Tanaka M; Izumi K; Watanabe T; Fujie S; Kawasaki T; Yoshimaru Y; Tateyama M; Setoyama H; Naoe H; Kikuchi K; Sasaki Y
    Cancer Med; 2015 Aug; 4(8):1214-23. PubMed ID: 26044168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial.
    Yoshimi F; Nagao T; Inoue S; Kawano N; Muto T; Gunji T; Ohnishi S; Imawari M
    Hepatology; 1992 Sep; 16(3):702-6. PubMed ID: 1324216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
    Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.